The Evaluate Vantage PD(L)anner – September 2022


Evaluate Vantage®
REPORT DOWNLOAD
Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been all about the clinical readouts, including the Tigit failure and the latest on Keytruda.